交易中 03-27 11:41:47 美东时间
-0.005
-0.45%
Boundless Bio (NASDAQ:BOLD) reported quarterly losses of $(0.58) per share which missed the analyst consensus estimate of $(0.52) by 11.54 percent. This is a 21.62 percent increase over losses of $(0.74) per share from
03-09 19:13
Gainers Inspira Technologies Oxy (NASDAQ:IINN) shares increased by 25.9% to $0...
02-09 20:05
2025年9月12日,意达利控股(00720.HK)旗下瀚德逊汽车迎来了其发展历程中的又一重要里程碑,瀚德逊电动货车首次批量启运瑞士,这标志着瀚德逊在欧洲市场的...
2025-09-15 16:01
Boundless Bio announces portfolio prioritization focusing on BBI-355 and BBI-825 combination therapy, and BBI-940 for its Kinesin program. The company extends its cash runway into early 2028, discontinues certain clinical trial arms, and plans to initiate new trials in 2025. A webcast on May 27 will provide further details.
2025-05-23 20:01